{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:54Z","timestamp":1793371014487,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaad.2026.08.091","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:18:27Z","timestamp":1787926707000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors and clinical impact of super-response in vitiligo patients treated with topical ruxolitinib: A real-world cohort study from a Turin Vitiligo Registry"],"prefix":"10.1016","author":[{"given":"Chiara Anna","family":"Fiasconaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cangialosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiulia","family":"Bailon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Milanaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2026.08.091_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm199","article-title":"The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma","volume":"2","author":"Spritz","year":"2010","journal-title":"Genome Med"},{"key":"10.1016\/j.jaad.2026.08.091_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2016.09.008","article-title":"Understanding mechanisms of autoimmunity through translational research in vitiligo","volume":"43","author":"Strassner","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"9988","key":"10.1016\/j.jaad.2026.08.091_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.091_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.091_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.091_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jid.2020.06.004","article-title":"The genetic basis of vitiligo","volume":"141","author":"Spritz","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"24","key":"10.1016\/j.jaad.2026.08.091_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417306","article-title":"Vitiligo: pathogenesis and new and emerging treatments","volume":"24","author":"Perez-Bootello","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.091_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","article-title":"Comorbidities in patients with vitiligo: a systematic review and meta-analysis","volume":"143","author":"Lee","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.jaad.2026.08.091_bib9","first-page":"343","article-title":"Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"issue":"450","key":"10.1016\/j.jaad.2026.08.091_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.091_bib11","article-title":"The pathogenesis and management of vitiligo","volume":"16","author":"Albelowi","year":"2024","journal-title":"Cureus"},{"issue":"10244","key":"10.1016\/j.jaad.2026.08.091_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.091_bib13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s13555-025-01381-7","article-title":"Efficacy and safety of ruxolitinib cream in vitiligo by patient characteristic subgroups: descriptive pooled analysis from two phase 3 studies","volume":"15","author":"Seneschal","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.091_bib14","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\"Superresponders\" at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.091_bib15","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.3390\/jcm14103480","article-title":"Super responders in moderate-to-severe atopic dermatitis under treatment with dupilumab: an explorative real-world study","volume":"14","author":"Mastorino","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.091_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2026.08.091_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.091_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamadermatol.2024.5737","article-title":"Combination of baricitinib and phototherapy in adults with active vitiligo: a randomized clinical trial","volume":"161","author":"Seneschal","year":"2025","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226034353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226034353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:27:33Z","timestamp":1793370453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226034353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S0190962226034353"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.091","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors and clinical impact of super-response in vitiligo patients treated with topical ruxolitinib: A real-world cohort study from a Turin Vitiligo Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}